Medications

Patients and clinicians using vedolizumab may be interested because the review links higher trough concentrations to better remission outcomes—most convincingly for endoscopic remission in UC—and provides descriptive...

A blood biomarker that helps predict primary non-response to anti‑TNF drugs could spare some patients ineffective therapy, reduce delays to alternative treatments, and inform shared decision‑making before starting...

Based on the title and source metadata, this appears to be an opinion or commentary related to Ulcerative colitis, Inflammatory bowel disease, and Medications. The original article is from Journal of Crohn's & colitis.

Single-cell and spatial multi-omics help explain why many patients do not respond to current biologics and JAK inhibitors and point toward molecular and cellular biomarkers that could one day guide more precise treatment...

The findings give clinicians and patients data on how often biologic therapy leads to endoscopic remission in biologic‑naïve patients with isolated small‑bowel Crohn's disease, and they suggest similar effectiveness...

Tofacitinib has been linked to increased risk of venous thromboembolism in other post‑marketing safety studies; this trial examines coagulation and platelet effects in UC patients, which could help clarify mechanisms and...

This trial tests whether starting with one biologic or targeted therapy versus another (and the sequence of switches) affects remission, safety, and quality of life for people with moderate-to-severe ulcerative colitis —...

If you're living with Crohn's disease, earlier and better diagnosis (for example, more cross-sectional imaging) may partly explain falling surgery rates over time. This study suggests system-level diagnostic improvements...

The findings suggest people with IBD on IV infliximab could switch to fixed-dose SC infliximab without losing drug exposure, and many may gain convenience and higher trough drug levels regardless of concomitant...

The analysis compares rescue drugs used when severe ulcerative colitis doesn't respond to IV steroids — a high-stakes situation where avoiding colectomy matters.

Postoperative endoscopic recurrence is common after ileocolonic resection for Crohn’s disease; this study suggests biologic drugs started after surgery are linked to lower recurrence rates. Knowing which biologics...

Researchers are testing whether blocking three inflammation pathways at once can reduce tissue inflammation more than single drugs. If ex vivo results show stronger effects, it could guide development of multi-target...

Patients with ulcerative colitis and their clinicians may be interested because the study tests whether adding pentoxifylline to standard mesalamine improves disease activity measured by the Mayo Score over 6 months.

Head-to-head comparisons between biologics are uncommon but useful for patients and clinicians deciding between agents. This study specifically compares ustekinumab and infliximab for remission, safety, and quality of...

Long-term safety information matters for people with ulcerative colitis considering or already taking filgotinib, because LTE studies track adverse events and lab changes over years. Findings from such a study can...

This study addresses whether continuing advanced biologic therapies around abdominal surgery raises short-term postoperative risks—important for IBD patients and clinicians planning surgery.

The study connects a genetic regulator (PACSIN2) and Rac1 signaling to cellular responses to mercaptopurine, a drug used in IBD, offering a possible explanation for why some patients experience thiopurine-related gut...

Biologics are commonly recommended for moderate-to-severe Crohn's disease and can change disease course by healing inflammation, so understanding their benefits, risks, and cost/access issues helps patients make informed...

Stopping Crohn's medications can cause flares and serious complications, and restarting treatment may be slower or less effective. Adherence and financial or practical support can help prevent these harms.

Treating fibrotic strictures would address an unmet need in Crohn’s disease — current approved drugs target inflammation, not established fibrosis. Positive Phase 2a signals could eventually lead to a new pharmacologic...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Medications. The original article is from Clinical and experimental gastroenterology.

Patients and clinicians often need real-world data on how methotrexate is actually used in IBD outside trials—this study shows it’s commonly paired with biologics, usually given subcutaneously, and has a median use of...

PG is a serious skin complication that can occur with UC. This report suggests guselkumab—an IL‑23 blocker used in IBD and dermatology—helped resolve PG in one patient without loss of UC remission, which could be...

People with UC often use probiotics or microbiome-directed therapies alongside prescription drugs. Understanding probiotic–drug interactions could explain why individuals respond differently to IBD treatments and may...

Surgery is still a core part of care for certain UC and Crohn's patients despite better medical therapies. Newer surgical techniques and coordinated medical–surgical approaches aim to reduce complications and recurrence...

Chronic antibiotic-refractory pouchitis is a common, impactful complication after ileal pouch-anal anastomosis that can worsen quality of life and increase the risk of pouch failure. Patients and clinicians need clearer...

A decreasing need for IBD-related surgery after pediatric diagnosis could mean fewer major operations and related recovery for children and young adults. It may reflect the growing use of advanced medical therapies in...

A common heart drug, verapamil, reduced disease signs in a mouse model of colitis and altered inflammation and the gut microbiota — suggesting a possible avenue for future IBD research. These are preclinical results, so...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Anti-TNF. The original article is from hmpgloballearningnetwork.com.

This trial tests whether adding nitazoxanide—an antiparasitic with reported antimicrobial and anti-inflammatory effects—can improve symptoms in people with mild-to-moderate ulcerative colitis. If effective, it could...

The paper identifies a molecular pathway (SERPINB5–MMP9–RLN2) by which the HDAC inhibitor trichostatin A reduced inflammation and protected the intestinal barrier in mouse and cell models of ulcerative colitis,...

The paper suggests that the same herbal formula can produce different absorbed components and target interactions depending on oral versus colonic delivery, which could influence therapeutic effects in ulcerative colitis...

Disease-related changes in liver drug-metabolizing enzymes may alter how herbal formulas or medications are processed in people with UC, potentially affecting efficacy or safety. Understanding the mechanisms helps inform...

The study identifies HK2 inhibition as a potential mechanism to shift pro-inflammatory macrophages and reduce intestinal inflammation in preclinical models, which could guide future drug development for IBD.

People with UC on tofacitinib may experience asymptomatic reactivation of HSV or VZV detectable by PCR, which could be relevant for infection monitoring and vaccination discussions. The study did not find clear links to...

Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...

PUC often behaves differently and more aggressively than adult-onset UC; understanding pediatric‑specific causes and treatments could lead to better, more effective therapies for children.

A pooled analysis of cardiovascular risk tied to advanced IBD therapies could affect treatment decisions and monitoring plans because some immune-targeted drugs have been linked to cardiovascular safety concerns in other...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease, Guselkumab, and IL-23 inhibitor. The original article is from Journal of clinical...

If true, using infliximab drug-level modeling plus routine blood tests could help predict who has mucosal healing without immediate endoscopy, potentially reducing invasive procedures and improving monitoring for people...

People with IBD and their clinicians need to know whether common IBD treatments change COVID-19 risk or should be stopped. This review provides practical recommendations (continue most maintenance drugs; avoid systemic...

The work identifies factors that predict loss of response to infliximab and suggests maintenance drug levels are the strongest predictor, which could influence monitoring strategies for people with Crohn's disease on...

Delivery method affects daily life and adherence. If you use or may use risankizumab, the on-body injector in this study was highly acceptable to most patients and caused mostly mild, local skin reactions, which may make...

Serum LRG1 is a candidate blood biomarker for mucosal inflammation in UC, but anti-TNF drugs may suppress its levels and cause false-negative results. This affects noninvasive monitoring and decisions based on LRG1...

Surgeons and other clinicians managing IBD patients need to understand current biologic and immunomodulator options, their risks, and implications for surgical timing and perioperative care.

Severe UC flares can produce extreme but reversible hyperglycemia that may look like new-onset diabetes, so patients and clinicians should monitor and re-evaluate glucose over time rather than assuming a permanent...

If you have isolated perianal fistulizing Crohn’s disease, this large multicenter cohort shows about one-third later developed luminal Crohn’s disease over long-term follow-up, but many did not — underscoring variable...

This paper links preclinical models and a short Phase 2a trial to show a candidate SIK2/SIK3 inhibitor (GLPG3970) produced anti-inflammatory and mucus-restoring signatures in IBD tissues. If findings hold in larger...